All individuals through age 26 should be vaccinated against HPV; for those aged 27 to 45, shared decision making is appropriate.
After reviewing data on efficacy, safety, and effectiveness accrued over the past decade, the Advisory Committee on Immunization Practices (ACIP) has updated its recommendations regarding human papillomavirus (HPV) vaccination in the U.S.
The recommendation to routinely immunize boys and girls starting at age 11 to 12 remains unchanged, but the upper age limit is now 26 for routine immunization in all individuals, with catch-up immunization recommended for those who were not vaccinated during early adolescence. Among persons aged 27 to 45, the benefit of immunization is substantially less, as the 9-valent vaccine (Gardasil 9; the only HPV vaccine currently distributed in the U.S.) is thought to protect against acquisition of new HPV types an…
Author
DisclosuresConsultant/Advisory BoardAicuris; Bayer; GSK; Innovative Molecules; Merck; MAPP Biopharmaceutical (Safety Monitoring Committee)
RoyaltiesUpToDate
Grant/Research SupportNIH/National Institute of Allergy and Infectious Diseases; GSK; Moderna; Assembly Biomedical; Aicuris
Editorial BoardsSexually Transmitted Diseases; Sexually Transmitted Infections; Journal of Infectious Diseases
Leadership PositionsID Division Chiefs Community of Practice (At-Large Member)
DisclosuresConsultant/Advisory BoardAicuris; Bayer; GSK; Innovative Molecules; Merck; MAPP Biopharmaceutical (Safety Monitoring Committee)
RoyaltiesUpToDate
Grant/Research SupportNIH/National Institute of Allergy and Infectious Diseases; GSK; Moderna; Assembly Biomedical; Aicuris
Editorial BoardsSexually Transmitted Diseases; Sexually Transmitted Infections; Journal of Infectious Diseases
Leadership PositionsID Division Chiefs Community of Practice (At-Large Member)